Case File
efta-efta00938143DOJ Data Set 9OtherFrom: Jeffrey Epstein <[email protected]>
Date
Unknown
Source
DOJ Data Set 9
Reference
efta-efta00938143
Pages
2
Persons
0
Integrity
Extracted Text (OCR)
Text extracted via OCR from the original document. May contain errors from the scanning process.
From: Jeffrey Epstein <[email protected]>
To: Julien Boillot
Cc: karem
Subject: Re: Spacs
Date: Tue, 26 Jun 2012 11:40:04 +0000
not exactly , but there are many pros and cons.. we buy an already existing spac„ many are for sale the we are
selling interests in the spc.. theree is no ipo involved.
On Tue, Jun 26, 2012 at 11:45 AM, Julien Boillot
wrote:
I had a close look at the various data on SPACs and I am not entirely certain it will work for us at least at the
holding level. I am certainly not ruling out the concept (which is very clever) and I outline below the issues
that I have (based on my understanding) for discussions purposes.
SPACs are by definition a pot of cash raised via an IPO in order to make the acquisition of an existing business
and fund, when necessary, its development. This raises two questions: (i) can we use a SPAC to make
acquisition of several companies in various sectors and (ii) can we use a SPAC to start a business from scratch.
From the information I gathered, SPACs are flexible structures and could therefore be setup to answer the
above questions but I have the feeling that by doing so, we may go away from the main objective of SPACs: a
visible quoted vehicle attracting liquidity and fair valuation. In our case, our investment company intends to
make acquisitions and invest in greenfield projects in various sectors in Africa, two reasons to apply a discount
to the holding company. I do not know whether my reasoning is correct and this is certainly a good topic for
discussions.
Going forward, I believe that we could create a type of company that answers almost all our requirements:
Ensuring a traded value for the investments made seems to be difficult at least in the first 2
years. For business acquired, we could introduced SPACs as "affiliates" of the Investment company.
Investco would try to retain control of the business.
Exit flexibility. This is a difficult one in both a limited company and limited liability
partnership (maybe more difficult in this latter case). I am not sure how this can be covered other
than on abest effort basis.
Interest of management aligned on that of investors. This can be done by either giving shares
to the management in a limited company or by granting the management a share of profits in a
limited liability partnership.
EFTA00938143
Avoid unexpected dilutions of initial investors. A similar concept of warrants can be put in
place in the case of a limited company. This is more difficult in a partnership as it will require a
heavier legal documentation. In this case, one has to think from the outsetwhat terms and
conditions will be offered to initial investors in the event of a second (or more) rounds of
contribution.
Other requirements ...
At this stage, I think we may have to stick to the original concept of an investment company be it a Limited
Liability Company or a Limited Liability Partnership. We are assessing the pros and cons of both options and
will revert soon.
Best regards,
J
The information contained in this communication is
confidential, may be attorney-client privileged, may
constitute inside information, and is intended only for
the use of the addressee. It is the property of
Jeffrey Epstein
Unauthorized use, disclosure or copying of this
communication or any part thereof is strictly prohibited
and may be unlawful. If you have received this
communication in error, please notify us immediately by
return e-mail or by e-mail to [email protected], and
destroy this communication and all copies thereof,
including all attachments. copyright -all rights reserved
EFTA00938144
Technical Artifacts (1)
View in Artifacts BrowserEmail addresses, URLs, phone numbers, and other technical indicators extracted from this document.
Email
[email protected]Related Documents (6)
DOJ Data Set 10OtherUnknown
EFTA01682184
186p
DOJ Data Set 10OtherUnknown
EFTA01370863
1p
Dept. of JusticeOtherUnknown
Medical Record/Clinical Encounter: DOJ-OGR-00026334
This clinical encounter document from the Bureau of Prisons details a medical evaluation of Jeffrey Epstein on July 12, 2019. It covers his medical history, current complaints, and treatment, including discussions around his triglyceride levels, sleep apnea, and back pain. The document was generated by the treating physician at the Metropolitan Correctional Center in New York.
1p
DOJ Data Set 8CorrespondenceUnknown
EFTA00014087
0p
DOJ Data Set 11OtherUnknown
EFTA02367961
1p
DOJ Data Set 10OtherUnknown
EFTA01977826
2p
Forum Discussions
This document was digitized, indexed, and cross-referenced with 1,400+ persons in the Epstein files. 100% free, ad-free, and independent.
Annotations powered by Hypothesis. Select any text on this page to annotate or highlight it.